目的 探讨芪苈强心胶囊联合尼可地尔治疗冠心病心绞痛患者的临床效果。方法 选取2016年1月-2017年5月三门峡市中医院收治的冠心病心绞痛患者142例，随机分成对照组（71例）和治疗组（71例）。对照组患者口服尼可地尔片，1片/次，3次/d；治疗组患者在对照组用药基础上口服芪苈强心胶囊，4粒/次，3次/d。两组患者均经过2个月治疗。观察两组患者临床疗效和心电图疗效，同时比较治疗前后两组患者心绞痛发作次数和持续时间、运动平板试验、CD105和基质金属蛋白酶-9（MMP-9）水平及不良反应。结果 治疗后，对照组临床有效率为81.69%，心电图疗效为85.92%，均分别显著低于治疗组的94.37%和97.18%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者心绞痛发作次数和持续时间均显著下降（P<0.05），且治疗组患者心绞痛发作次数和持续时间明显少于对照组（P<0.05）。治疗后，两组患者平均运动时间和运动负荷量显著升高（P<0.05），运动ST段压低显著降低（P<0.05），且治疗后治疗组患者运动平板试验结果明显好于对照组（P<0.05）。治疗后，两组患者CD105水平和MMP-9水平均显著降低（P<0.05），且治疗组患者CD105和MMP-9水平明显低于对照组（P<0.05）。治疗期间，对照组患者不良反应发生率为16.90%，显著高于治疗组的4.23%，两组患者比较差异具有统计学意义（P<0.05）。结论 芪苈强心胶囊联合尼可地尔治疗冠心病心绞痛疗效明显，安全性高，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Qili Qiangxin Capsules combined with nicorandil in treatment of angina pectoris of coronary heart disease. Methods Patients (142 cases) with angina pectoris of coronary heart disease in the Chinese Medicine Hospital of Sanmenxia City from January 2016 to May 2017 were randomly divided into control (71 cases) and treatment (71 cases) groups. Patients in the control group were po administered with Nicorandil Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical and electrocardiographic efficacy was evaluated, and the frequency and duration of angina pectoris, the treadmill exercise test, the CD105 and MMP-9 Levels, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.69%, and the electrocardiographic efficacy was 85.92%, which were significantly lower than 94.37% and 97.18% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P<0.05), and the frequency and duration of angina pectoris in the treatment group after treatment was significantly less than that in the control group (P<0.05). After treatment, the average exercise time and exercise load in two groups was significantly increased (P<0.05), the exercise ST depression was significantly decreased (P<0.05), and the treadmill exercise test result in the treatment group after treatment was significantly better than those in the control group (P<0.05). After treatment, the CD105 and MMP-9 levels in two groups were significantly decreased (P<0.05), and the CD105 and MMP-9 levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 16.90%, which was significantly higher than 4.23% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Qili Qiangxin Capsules combined with nicorandil in treatment of angina pectoris of coronary heart disease has obvious curative effect and high safety, which has a certain clinical application value.